Revolution Medicines, Inc. annual report, FY2023

Revolution Medicines, Inc. — FY2023 Form 10-K

Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report. Revolution Medicines is a clinical-stage precision oncology company developing therapies for RAS-addicted cancers; it had no products approved for sale and no product-sales revenue.

Financial results and liquidity

Metric	FY2023	FY2022
Revenue, all collaboration revenue	$11.6 million	$35.4 million
Research and development expense	$423.1 million	$253.1 million
General and administrative expense	$75.6 million	$40.6 million
Operating loss	$487.2 million	$258.3 million
Net loss	$436.4 million	$248.7 million
Net loss per share, basic and diluted	$3.86	$3.08
Cash used in operating activities	$350.6 million	$224.4 million

• Revenue fell 67%, primarily because Sanofi reimbursed fewer research and development costs; the Sanofi collaboration terminated in June 2023.
• R&D expense rose 67%, led by higher RMC-6236 clinical-trial and manufacturing costs, increased staffing, preclinical work, and clinical development of RMC-9805 and RMC-6291. G&A expense rose 86%, including acquisition-related costs and stock-based compensation.
• Cash, cash equivalents and marketable securities totaled $1.853 billion at year-end, compared with $645 million at December 31, 2022. Management said available funds were expected to support planned operations for at least 12 months after the report date; additional capital will be needed to pursue longer-term development and commercialization.
• No borrowings are reported in the balance sheet. Liabilities included $87.9 million of operating lease obligations and $6.5 million of warrant liability. Current assets were $1.879 billion and current liabilities $143.9 million.
• Operating margin and product margins are not meaningful measures for this pre-commercial company. The filing reports no commercial product sales.

Material changes and notable items

• EQRx acquisition: Completed November 9, 2023. Revolution Medicines issued approximately 54.8 million shares and acquired net assets of $1.153 billion, principally cash and marketable securities. The transaction was accounted for primarily as a capital-raising transaction with an asset-acquisition component. Acquisition-related severance and accelerated equity awards contributed to 2023 expenses.
• Net loss increased by $187.7 million year over year, while operating cash use increased by $126.2 million. Higher interest income ($47.5 million versus $9.2 million) partially offset the larger operating loss.
• Financing cash flow was $1.229 billion, including $840.8 million of cash and restricted cash acquired in the EQRx transaction, $323.7 million net from a March 2023 stock offering, and $62.1 million net from the at-the-market program. The acquisition and equity financings materially increased cash but also diluted existing shareholders.

Pipeline, outlook and risks

• RMC-6236: Phase 1/1b monotherapy data reported in 2023 showed preliminary activity in RAS-mutated NSCLC and PDAC. At the October 2023 data cut, efficacy-evaluable patients had reported ORRs of 38% in NSCLC and 20% in PDAC, with DCRs of 85% and 87%, respectively. These were interim, early-stage results from limited patient groups, not pivotal-trial evidence. The company reported improved response rates with additional follow-up in January 2024.
• Management expected updated RMC-6236 NSCLC and PDAC data in the second half of 2024, and initial expansion-cohort data in the second or third quarter of 2024. It planned to initiate randomized Phase 3 studies in previously treated RAS-mutated NSCLC and PDAC in the second half of 2024, subject to regulatory feedback and further data.
• RMC-6291: Ongoing Phase 1b study showed preliminary clinical activity in KRAS G12C NSCLC and colorectal cancer, with generally tolerated dosing reported at the October 2023 cutoff. The company continued dose evaluation at 200 mg twice daily and expected initial combination-study data in the second half of 2024.
• RMC-9805: Ongoing Phase 1/1b dose escalation; management reported oral bioavailability and favorable interim tolerability, with no dose-limiting toxicities reported at that time. A recommended Phase 2 dose had not been reached. Initial data were expected in the second half of 2024.
• Key risks include clinical-trial failure or delay, uncertain translation of preliminary results into pivotal outcomes, adverse effects, patient-enrollment challenges, competition, reliance on contract manufacturers and clinical-trial vendors, intellectual-property uncertainty, and the need for substantial additional financing. The company expects continuing losses and has never generated product-sales revenue.
• Other notable exposures include long-term Redwood City leases, potential dilution from equity awards and future financing, and possible effects of geopolitical disruptions on trials and supply chains. Management reported no litigation expected to have a material adverse effect. The auditor gave unqualified opinions on the financial statements and internal control over financial reporting.

Investor verification priorities

• Check subsequent clinical disclosures and trial registrations for final, adequately followed-up efficacy and safety results, patient counts, dose selection, and regulatory alignment for the planned Phase 3 trials.
• Track operating cash burn against the stated runway, future trial costs, and any additional equity or debt financing; assess the dilution associated with the EQRx share issuance and remaining equity instruments.
• Review the composition, maturity, liquidity, and credit exposure of the cash and marketable-securities portfolio, as well as lease commitments and warrant and earn-out terms.
• Confirm the consequences of Sanofi collaboration termination and the status of remaining partner- or investigator-sponsored programs, including RMC-4630 and RMC-5552.
• Monitor manufacturing capacity, trial enrollment, safety signals, competitive progress, and patent protection for the lead RAS(ON) programs.